<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Valacyclovir - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Valacyclovir</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Valacyclovir</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Valacyclovir 500mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Herpes zoster (shingles)</strong>
            <ul>
              <li>1000 mg (2 x 500 mg tablets) PO three times daily for 7 days</li>
              <li>Most effective if started within 72 hours of rash onset</li>
            </ul>
          </li>
          <li><strong>Genital herpes (first episode)</strong>
            <ul>
              <li>1000 mg (2 x 500 mg tablets) PO twice daily for 10 days</li>
            </ul>
          </li>
          <li><strong>Genital herpes (recurrent episode)</strong>
            <ul>
              <li>500 mg PO twice daily for 3 days (or 1000 mg once daily for 5 days)</li>
              <li>Most effective if started at first sign of prodrome or lesions</li>
            </ul>
          </li>
          <li><strong>Herpes labialis (cold sores)</strong>
            <ul>
              <li>2000 mg (4 x 500 mg tablets) PO twice daily for 1 day (total 2 doses, 12 hours apart)</li>
              <li>Start at earliest sign of cold sore (tingling, itching)</li>
            </ul>
          </li>
          <li><strong>Dose adjustments for renal impairment</strong>
            <ul>
              <li>CrCl 30–49 mL/min: reduce dose by ~50% (e.g., 1000 mg BID for zoster instead of TID)</li>
              <li>CrCl 10–29 mL/min: 1000 mg once daily for zoster; 500 mg once daily for genital herpes</li>
              <li>CrCl &lt;10 mL/min or dialysis: 500 mg once daily for zoster</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Herpes zoster (shingles) treatment</li>
          <li>Genital herpes (HSV-2) treatment (initial and recurrent episodes)</li>
          <li>Herpes labialis (cold sores / HSV-1) treatment</li>
          <li>Varicella zoster virus (VZV) and herpes simplex virus (HSV) infections in immunocompetent adults</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to valacyclovir, acyclovir, or any component</li>
          <li>Renal impairment: dose adjustment required; risk of neurotoxicity and renal dysfunction with standard doses</li>
          <li>Dehydration: ensure adequate hydration to reduce risk of renal crystallization</li>
          <li>Immunocompromised patients: may require higher doses and longer duration; follow specialist guidance</li>
          <li>Pregnancy/breastfeeding: generally considered safe when indicated (converted to acyclovir); discuss risk/benefit</li>
          <li>Thrombotic microangiopathy risk in severely immunocompromised patients (rare)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Headache, nausea, abdominal pain</li>
          <li>Dizziness, fatigue</li>
          <li>Renal dysfunction (especially in dehydration or pre-existing renal disease)</li>
          <li>CNS effects (confusion, hallucinations, seizures) — rare, more common in renal impairment or high doses</li>
          <li>Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) — very rare, mainly in immunocompromised</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO tablet; may take with or without food</li>
          <li>Ensure adequate hydration during therapy to reduce risk of renal crystallization</li>
          <li>Start as early as possible: within 72 hours for zoster, at first sign of prodrome for recurrent HSV</li>
          <li>Complete full course even if symptoms improve</li>
          <li>Counsel on transmission prevention: avoid contact with lesions, use barrier protection for genital herpes, avoid kissing/sharing utensils for oral herpes</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response: reduction in pain, lesion crusting/healing, resolution of new lesion formation</li>
          <li>Renal function if prolonged therapy or pre-existing renal impairment (ensure hydration, monitor for oliguria)</li>
          <li>CNS symptoms: confusion, agitation, hallucinations (especially in older adults or renal impairment)</li>
          <li>For zoster: monitor for post-herpetic neuralgia (PHN); consider analgesics and referral if pain persists after rash heals</li>
          <li>Complications: bacterial superinfection, ophthalmic involvement (zoster ophthalmicus), disseminated disease</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Herpes zoster: start within 72 hours of rash onset for maximum benefit; older adults and immunocompromised patients benefit most from early treatment</li>
          <li>Ophthalmic zoster (V1 dermatome, lesions on nose tip): requires urgent ophthalmology evaluation—arrange evacuation</li>
          <li>Disseminated zoster or severe presentations: consider IV acyclovir (if available) and evacuation</li>
          <li>Ensure hydration status adequate before starting therapy and throughout treatment—risk of renal dysfunction in dehydrated patients</li>
          <li>If renal function unknown and patient has risk factors (older age, diabetes, hypertension), use lower doses or extend dosing intervals</li>
          <li>Document dose, indication, start date, and planned duration; counsel on completing full course</li>
          <li>For genital herpes: encourage testing for other STIs when feasible and partner notification/treatment per local guidelines</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (valacyclovir tablets): <a href="https://pdf.hres.ca/dpd_pm/00069421.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00069421.PDF</a></li>
          <li>Health Canada product monograph (Valtrex – valacyclovir reference): <a href="https://pdf.hres.ca/dpd_pm/00017875.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00017875.PDF</a></li>
          <li>Medscape reference (valacyclovir): <a href="https://reference.medscape.com/drug/valtrex-valacyclovir-342578" target="_blank" rel="noopener">https://reference.medscape.com/drug/valtrex-valacyclovir-342578</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
